Short infotainment formats are popular among viewers - for example, before the news or between two movies. The Canadian biotech startup Defence Therapeutics has now been chosen by the series "Viewpoint with Dennis Quaid" as a partner for a series on the opportunities and limitations of biotechnology. For the Company, which is aiming for the Nasdaq, the associated publicity can only be beneficial. What remains decisive, however, is what happens behind the camera. Groundbreaking research is currently underway.
More is better. According to this motto, the innovative cancer specialist Defence Therapeutics has built an extensive patent portfolio in recent years. Here we discuss the areas in which patents have been filed, what options Defence Therapeutics has as a result, and what will be crucial for the Company, which is facing several clinical trials in 2023 in the coming weeks.
The first series of tests under real road conditions went better than expected for the hydrogen innovator based in Vancouver and London, clearly demonstrating the advantages of hydrogen fuel cell-powered light commercial vehicles with a range of over 500 km compared to battery-electric vans and internal combustion engines. Following in the footsteps of fleet management provider Rivus, which is responsible for managing over 120,000 light commercial vehicles and trucks annually, utility company SSE, which currently maintains one of the largest vehicle fleets in the UK, is now entering the test series. If the results continue to confirm the positive trend, First Hydrogen faces a golden future in the billion-dollar market for climate-neutral vehicles.
In times of crisis like now, the urgency in the supply of strategic metals becomes very apparent. Currently, China is the majority owner of these elements, with 70%. With further escalations in Ukraine and global instabilities, access to key resources is essential, as long-established supply routes can be suspended overnight. Rare metals are crucial for various modern technologies, from smartphones to wind turbines and defense equipment. China could impose an export ban on key raw materials to achieve its strategic goals in Taiwan and exclude the West from supply. This is political leverage that can only be softened by consistently building alternatives. Almonty Industries has 4 major tungsten properties in Spain, Portugal and South Korea. Soon the largest mine will go into production.
Cancer specialist Defence Therapeutics has applied for international patent protection for its versatile Accum™ adjuvant technology. This means that the numerous projects the Company is driving forward in parallel thanks to its platform approach will soon receive a "price tag". Specifically, this involves vaccines against various types of cancer, ranging from skin to pancreatic cancer, some of which will soon be transferred to a Phase I study. The same applies to the promising chemotherapeutic AccuTOX™. We discuss the outlook for the CRISPR "gene scissors," which mRNA study will soon deliver results and the state of takeover activity in the industry.
The question is valid. Is it another tale from "One Thousand and One Nights" like in previous years, or will the ambitious US hydrogen company, led by CEO and marketing specialist Andy Marsh, keep its word this time? After the publication of the ambitious growth targets up to the year 2030 on the occasion of the specially organized Analyst Day, the Plug Power share shot up by more than 60% at its peak. This indicates investors still believe in the story of the fuel cell pioneer. However, the next few months will show whether it can be successfully implemented. Blind faith is likely to be clouded once again by a major capital measure.
Curing skin cancer, lymphoma, lung cancer and even pancreatic cancer - the list of promising projects Defence Therapeutics is advancing is long. But despite the wide range of services, Defence Therapeutics' projects go hand in hand. The reason lies in the Accum™ technology, whose platform approach is now protected by the US Patent Office. Below you can find out about the current status of Defence Therapeutics' projects, where the journey may take us in the coming weeks, and in which area Defence Therapeutics could spring a surprise.
Things continue to go like clockwork at hydrogen innovator First Hydrogen. The Vancouver and London-based company reported better-than-expected test results for its hydrogen fuel cell-powered light-duty vehicles under real-world road conditions. The range of 500 km was exceeded. The Company is also making rapid progress in establishing a complete value chain with the production and distribution of green hydrogen. Despite its excellent business performance, the stock of First Hydrogen has experienced a decline in line with the overall industry trend, which may present an attractive entry opportunity from a long-term perspective.
Governments worldwide agree: Achieving a real turnaround in the fight against global warming requires joint, open discussions about existing technologies and necessary innovations for a more sustainable use of existing resources. The path to a CO2-free future is costly and requires extremely high investments. Green hydrogen is an important building block. The Norwegian pioneer Nel ASA has been well on its way as a global player for several years, but the Company is not yet profitable. However, recent blockbuster orders point to a noticeable acceleration. Here is an assessment of the situation.
Varta AG was one of the high flyers in the MDAX in 2020/2021. The rally led the stock price to over EUR 180 on the expectation of a battery revolution from Ellwangen. But things turned out differently. Problems with the supply chains due to the Corona pandemic, rising raw material and energy costs and sales problems with key customers caused the Group to stumble. Today, 2 years after the joyful rush, the Varta share price has plummeted by 90% and a tough restructuring course is on the agenda. A stocktaking.